AHS 2022 | AHS highlights: atogepant and zavegepant for migraine treatment

Stewart Tepper, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, gives an update on the Phase III PROGRESS trial (NCT03855137) of atogepant for the prevention of chronic migraine. Individuals treated with 60 mg atogepant once daily had seven fewer mean monthly migraine days. Based on these results, atogepant will be submitted to the FDA for regulatory approval for the preventive treatment of chronic migraine. Approval of this expanded indication would make atogepant the first in the gepant class available for prophylactic treatment of both episodic and chronic migraine. Another study showed that atogepant was associated with a dose-dependent decrease in body weight compared with placebo and standard care. Furthermore, Dr Tepper discusses the results of the Phase III double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of zavegepant nasal spray for the acute treatment of migraine. Based on that study’s positive results, zavegepant has been submitted to the FDA for approval – marking the potential for another treatment available for migraine patients. This interview took place at the 2022 American Headache Society (AHS) Meeting in Denver, CO.